# A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

Study · id `cardio:ct-nct07481981` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07481981](<https://clinicaltrials.gov/study/NCT07481981>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07481981

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 344 participants.

## Technical summary

Registry record NCT07481981. Randomized; double masking; primary purpose treatment. Start 2026-07-21 (actual); primary completion 2028-12-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 344 participants (planned count; ClinicalTrials.gov record NCT07481981, source copy `cardio:ctgov-nct07481981-2026-10-13`, retrieved 2026-10-31)
- Started: 2026-07-21 (actual) (ClinicalTrials.gov record NCT07481981, source copy `cardio:ctgov-nct07481981-2026-10-13`, retrieved 2026-10-31)
- Primary completion: 2028-12-28 (anticipated) (ClinicalTrials.gov record NCT07481981, source copy `cardio:ctgov-nct07481981-2026-10-13`, retrieved 2026-10-31)
- Completion: 2029-01-28 (anticipated) (ClinicalTrials.gov record NCT07481981, source copy `cardio:ctgov-nct07481981-2026-10-13`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Israel; Japan; New Zealand; South Korea; Taiwan (ClinicalTrials.gov record NCT07481981, source copy `cardio:ctgov-nct07481981-2026-10-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07481981-2026-10-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
- Acronym: PALM-PAH
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Treprostinil Palmitil Inhalation Powder
- Intervention (Drug): Placebo
- Lead sponsor: Insmed Incorporated
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Insmed Incorporated (`cardio:org-insmed-incorporated`)

## Provenance

Content hash: 48474aba12714474ec9f738a8b2796fbc4f46a4baf3ca95dd5f4a57ef20cdb97
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
